Metatrolide : Metatrolide (with effects similar to semaglutide)acts as a GLP-1 agonist to regulate blood sugar levels, promote insulin secretion, and inhibit glucagon, effectively stabilizing blood sugar and reducing the risk of diabetes
Altogether, the long-term aftermath of COVID-19 poses a great awareness in the global socioeconomic environment, with an estimation that approximately 30% of the pandemic health burden might arise from COVID-19-induced disability [5, 6]
Tirzepatide: A novel glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist for the treatment of type 2 diabetes: The first twincretin
Early studies show up to 24% body weight reduction in 48 weeks surpassing current GLP-1 drugs
Chavda V, Yadav D, Patel S, Song M (2024) Effects of a Diabetic Microenvironment on Neurodegeneration: Special Focus on neurological cells